Richard Ranieri has been appointed to the newly created position of executive vice president, Human Resources and Administration, and Julio Casoy, M.D. has been appointed senior vice president, Medical Affairs, at Sepracor.
   
Mr. Ranieri joins the company from Neurocrine Biosciences, where he was senior vice president and chief administrative officer. Mr. Ranieri managed and directed the company’s human resources function and its corporate communications, operations and purchasing. He also served as a corporate officer and was a member of the senior management team as well as secretary to the compensation committee of the board of directors. Prior to Neurocrine, he served as senior vice president, Human Resources at Genencor International for 12 years. Prior to joining Genencor, Mr. Ranieri spent more than 15 years with GlaxoSmithKline where he held a variety of human resources and sales management positions.
   
Dr. Casoy joins the company from Shire Pharmaceuticals where he served as senior vice president, Global Medical Affairs since 2005. Dr. Casoy was responsible for providing direction and oversight for all medical affairs activities supporting Shire’s drug development programs and marketed products worldwide. In addition, he was responsible for developing and directing objectives, policies and programs pertaining to global medical affairs activities and responsibilities and was a member of the R&D leadership team. Prior to Shire, he served as vice president of Global Medical Affairs, Compliance and intercontinental medical director at Wyeth.
   
“I am pleased to announce the addition of such accomplished professionals to Sepracor’s human resource and research and development teams,” said Adrian Adams, president and chief executive officer. “Richard brings with him a wealth of successful human resource, operational and general management experience, and his leadership skills will be integral to our plan and vision for continued organizational growth. Julio’s appointment to lead our medical affairs organization supports our focus on deepening and broadening our management team’s strength and capabilities and reinforces our objective of delivering enhanced performance and productivity across our commercial and research and development organizations.”